A senior Trump administration health official is facing fresh scrutiny after an ethics watchdog requested an investigation into her financial interests and involvement in a federal hormone therapy policy announcement. The Alicia Jackson conflict of interest allegations centre on claims that she publicly supported a policy change while holding stock in a company connected to menopause treatment.
The Campaign Legal Center has asked the Department of Health and Human Services inspector general to examine whether Alicia Jackson violated federal ethics requirements.
Jackson leads the Advanced Research Projects Agency for Health, an agency that invests taxpayer money in medical technology and research.
The complaint follows a ProPublica investigation that raised questions about Jackson’s financial interests and whether she should have recused herself from public statements concerning hormone replacement therapy.
Alicia Jackson Conflict of Interest Allegations Explained
According to ProPublica, Jackson publicly supported a federal policy change involving hormone replacement therapy products while owning stock in Evernow, a company she founded that connects women with menopause treatments.

Jackson reportedly held at least $115,000 in Evernow stock, alongside an unknown amount of stock options, according to her financial disclosures.
The issue centres on a decision announced by the Department of Health and Human Services to remove certain black-box warnings from hormone replacement therapy products.
Black-box warnings are the strongest safety warnings required by the Food and Drug Administration.
Jackson appeared at an HHS press conference announcing the policy change in November 2025. She was also quoted in a department news release concerning the decision.
The Campaign Legal Center argues that her financial connection to Evernow created a potential conflict that should be investigated.
Watchdog Questions Whether Federal Ethics Rules Were Followed

Federal employees are generally prohibited from participating personally and substantially in government matters that could affect their financial interests.
These restrictions are intended to prevent public officials from using government positions in ways that could benefit their private investments.
The Campaign Legal Center wants the inspector general to determine whether Jackson should have recused herself from participating in the policy announcement.
The organisation also questioned whether Jackson obtained an ethics waiver that would have allowed her to participate despite the potential conflict.
Neither Jackson nor HHS has publicly explained whether such a waiver existed.
The complaint also raises questions about financial disclosures involving Jackson and her husband.
Questions Over Investments Worth Hundreds of Millions

The ethics complaint goes beyond Jackson’s investment in Evernow.
The Campaign Legal Center questioned whether she properly disclosed underlying assets connected to investment funds held by her husband’s investment firm.
ProPublica reported that Jackson disclosed ownership of more than 60 venture capital and private equity funds. She said those funds did not disclose their individual holdings to investors.
The watchdog wants investigators to determine whether the disclosures provided enough information to identify potential conflicts involving healthcare companies.
It also identified investments in another company connected to menopause hormone treatments.
The reported value of some underlying assets could reach hundreds of millions of dollars, making the disclosure questions particularly significant.
However, the existence of investments does not automatically establish that Jackson influenced government policy to benefit herself or her business interests.
The investigation is intended to establish whether she followed the ethics requirements governing federal employees.
Jackson Placed on Administrative Leave
ProPublica reported that Jackson had been placed on administrative leave.
Health officials have not publicly explained the reason for that decision.
The timing has added to questions surrounding the controversy, although it does not establish that the leave resulted from the ethics allegations.
The Department of Health and Human Services has also not publicly provided a detailed response to the watchdog’s concerns.
The Campaign Legal Center is asking the inspector general to examine the circumstances surrounding Jackson’s financial interests, public statements and disclosures.
An inspector general investigation could help establish whether the official followed federal ethics rules and whether additional action is necessary.
Why the Case Matters for Public Trust
The Alicia Jackson conflict of interest allegations raise broader questions about financial transparency in government.
Federal officials often make decisions that affect major industries, including healthcare, technology, pharmaceuticals and financial services.
When an official has investments connected to an area of public policy, the public deserves confidence that decisions are made in the public interest.
That is why federal ethics rules require disclosure and, in certain circumstances, recusal from decisions that could affect personal financial interests.
At this stage, the watchdog has requested an investigation. No final finding has established that Jackson violated federal law or improperly influenced the hormone therapy policy.
The inspector general’s review could determine whether the concerns have merit.
For now, the case has placed another Trump administration official under scrutiny and renewed debate about financial conflicts among senior government employees.
